IPSEN (OTCMKTS:IPSEY) Short Interest Update

IPSEN (OTCMKTS:IPSEY) was the target of a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 37 shares, a drop of 92.8% from the May 14th total of 514 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 2,616 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

IPSEY has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, HC Wainwright initiated coverage on shares of IPSEN in a research report on Friday. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, IPSEN has a consensus rating of “Hold”.

IPSEN Stock Performance

IPSEN stock remained flat at $46.75 during mid-day trading on Tuesday. 339 shares of the company’s stock traded hands, compared to its average volume of 744. IPSEN has a 52-week low of $28.66 and a 52-week high of $51.10. The firm’s 50 day moving average price is $47.94 and its two-hundred day moving average price is $42.84.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).